Park City, UT

3 days / 6 sessions
Current Issues in Spine

February 2-4, 2017

Oska-Pulse-Golf-350x350-2.jpg

June 5, 2017 OrthoSpineNews

CARLSBAD, CA, June 1, 2017 – Oska Pulse, a breakthrough wearable electromagnetic field device that eases pain, was recently named “Best Product” at the 27th Annual ING Spring Conference. Oska Pulse, the flagship product from Oska Wellness, received the award last month at the World Golf Village & Hall of Fame in St. Augustine, FL.

The ING Spring Conference is an annual gathering of media and golf industry executives conducted by the non-profit networking organization, the International Network of Golf. A group of 130 industry executive and media were in attendance at this years’ event, held May 21- 24.  The Oska Pulse and the Knuth Golf High Heat fairway metals tied in voting by attendees who chose their favorite products which were demoed at the conference.

“We are thrilled to be honored by the folks who attended the ING Conference and who recognize Oska’s mission to provide non-invasive, drug free pain management solutions,” said Greg Houlgate, CEO of Oska Wellness. “It was an inspirational week at the conference, and we heard from golfers who deal with elbow, hip, wrist, knee, back pain and more. With Oska Pulse, golfers can play another round — pain free.”

During the PGA Merchandise Show in January, Oska Wellness introduced Oska Pulse, a hands-free device that employs safe Pulsed Electromagnetic Field (PEMF) therapeutic technology to help people enjoy more active, pain-free and drug-free lives. Oska Pulse was named “best in show” by top golf media outlets who attended, including Golf Digest, Golf Channel, and TravelingGolfer.net.

Oska Pulse is a safe, easy-to-use, portable and wearable health technology product designed to help reduce muscle stiffness, temporarily relieve minor pain and increase mobility for people who have acute or chronic pain.

About Oska Wellness
Oska, Inc. is committed to developing health and wellness technology-driven products that assist individuals in living a more active, pain-free lifestyle. Oska Pulse utilizes patented eTec Pulse Technology that specifically optimizes Pulsed Electromagnetic Field (PEMF) therapeutic technology, similar to the PEMF therapies used in many clinical applications for accelerating the body’s ability to heal itself.

The science and technology behind Oska Pulse was engineered and developed by a team of respected scientists and researchers with more than 25 years of experience in engineering health and wellness technologies to treat pain. Oska Wellness, Inc. does not claim the product to diagnose, treat, cure or prevent any medical condition. The company is headquartered in Carlsbad, California and can be found online at www.oksawellness.com.

 

ADD COUPON CODE  “ORTHOSPINECO”  FOR  $55.00 OFF

READ MORE ABOUT OSKA HERE

 

 

 


niams-19_l-1.jpg

June 5, 2017 OrthoSpineNews

June 1, 2017

DAYTON, Ohio – The Accelerant Venture Capital Fund recently approved investment in AMB Surgical to support the company’s development of a prototype for its Flyte Automated Growing Rod, a medical device that could revolutionize the way physicians treat juvenile scoliosis, lengthen limbs, and stabilize traumatic injuries.

The company founders bring decades of engineering experience to their work, as well as a personal mission to make such surgeries less traumatic for young patients.

Founder Casel Burnett would know. His daughter was diagnosed with juvenile scoliosis as a young child and endured years of invasive surgeries as part of the treatment. Scoliosis, or curvature of the spine, can lead to life-long health issues if not corrected while the child is still growing. Watching his daughter undergo treatment motivated him to find a better way.

“AMB embodies the innovative spirit and hard work that characterize the Dayton Region,” said Roger Edwards, Vice President of Accelerant Venture Capital Fund, an initiative of the Dayton Development Coalition. “Their work has the potential to revolutionize the way these conditions are treated and spare young patients repeated, invasive procedures.”

Burnett is a mechanical engineer and group manager of production engineering at Toyota, and partnered with friend Tyson Ross, an electrical controls engineer and program manager at the U.S. Air Force Research Laboratory, to see how they could take the existing technology and improve it. Ross and Burnett are confident they have found the answer.

AMB uses patented technology to electronically control the extension of rods used in orthopedic surgeries. Current devices use manual adjustments, either by having caretakers, such as parents, use tools to adjust an external framework for limb extension, or, for scoliosis, through repeated back surgeries. A physician implants an adjustable rod along the child’s spine, and as the child grows, uses tools to lengthen the rod through additional surgeries to correct the curve.

Flyte would allow the physician to expand the rod remotely, without surgery, as the child grows, both cutting down on the number of surgeries and potentially accelerating the treatment. It would eliminate the need for parents to adjust external frames, as well as reduce the likelihood of missing adjustments.

The key to their technology is tiny gear box located in the rod that has a microchip and RFID reader to program adjustments and record information.

Dr. Michael Albert, Director or Orthopaedics at Dayton Children’s Hospital, called the product a “game changer” in this type of treatment.

“We have made significant progress in the safety and design of limb lengthening external fixator devices, but what has been lacking is an automated, safe and reliable device that removes the patient or family from making daily adjustments,” Dr. Albert wrote in a letter of support for AMB.

Ross said they plan to develop a prototype with the current round of funding, starting with a rod that would be used in external frames, then moving on to implanted rods for scoliosis treatment and other internal uses.

For physicians, the device would also provide valuable feedback they can’t access today. The same technology that allows the device to adjust, allows it to collect data on the patient’s progress. The company already holds patents on the technology, and the initial research and design have generated interest from world leaders in pediatric orthopedic surgery.

“How small can we go? That’s the real question,” Ross said. “There’s tremendous potential for this type of technology, and we are confident we can bring it to market.”

The product would need to undergo testing and approval from the Federal Drug Administration.

The investment marks the 10th investment for Accelerant, the region’s only institutional VC fund with resources ready to invest in local companies. AMB has attracted significant “sidecar” investment as well, as private local investors find increasing opportunities to invest in start-ups in the Dayton Region.

“In the last year, we’ve seen a real shift in funding for local start-ups,” Edwards said. “The support and investment of local ‘angel investors’ is vital for start-ups to flourish. It’s exciting to connect local entrepreneurs to investors in the Dayton Region so they can grow their businesses here.”

AMB’s technology has generated interest from outside the Dayton region, as well. Dan Sands, a 25-year healthcare industry executive, has identified and is retaining world-renowned surgeon advisors, subject matter experts in engineering, accredited investment sources, and potential strategic commercialization entities.

“The positive market interest for this technology has been extraordinary,” said Sands, CEO of D11, LLC, who has spent most of his career in Warsaw, Ind., a city known within the industry as the “Orthopaedic Capital.” “Flyte’s ability to give surgeons real-time biomechanical stress/strain data will allow more accurate and timely remote non-surgical adjustments. This represents a game changing advancement in orthopaedics and could lead to a new frontier in bionic implantable devices that improves the total cost and quality of care.”

AMB plans to engage The Ohio State University’s Center for Design and Manufacturing Excellence and other expert resources as part of its efforts to develop the initial productionready prototypes. The Ohio State center plans to leverage its expertise to facilitate design feasibility, component and systems development, prototyping, manufacturing scale, and workforce development. “Working with Ohio State’s CDME brings resources and expertise to the process at an early stage that is difficult to find elsewhere in the country,” Ross said.

As for the young girl who inspired this technology, Burnett’s daughter Ashley Mae is all grown up, working as a nurse, and in great health. She’s the name behind AMB.

“We started down this path to help her, and I hope the work we’ve done will give children an easier journey than she had,” Burnett said. “We’re grateful for the support we’ve found here in Dayton and are excited to move forward with this opportunity.”

Dayton Development Coalition (DDC) is the leading economic development organization for the 14- county Dayton region. Working closely with public and private regional partners, its mission is to retain, expand and recruit jobs. The DDC and the Dayton region ranked as the nation’s top metro for its size for economic development in 2008, 2009 and 2012 and runner-up in 2010, 2011, 2014 and 2015. With the State’s largest single-site employer in its backyard, the DDC also focuses on advocating for the critical missions at Wright-Patterson Air Force Base and supporting the work of the United States Air Force. The DDC was ranked as America’s top military community, and was presented with the 2015 Community Excellence Award from the Association of Defense Communities. It was designated as one of the ADC’s Great American Defense Communities in 2016 – a testament to the collaborative efforts in support of Wright-Patt, America’s #1 Air Force Base as ranked by the Air Force Times (2014). For any questions regarding the DDC, contact Shannon Joyce Neal at (937) 723-2047. For more information on AMB, contact Dan Sands, 574-527-1525, or dan.sands@outlook.com.

For any questions regarding the DDC, contact Shannon Joyce Neal at (937) 723-2047. For more information on AMB, contact Dan Sands, 574-527-1525, or dan.sands@outlook.com.


Exogen-Bioventus-Ultraschall-23524254-Exogen-B_1-1-1200x1200.jpg

June 5, 2017 OrthoSpineNews

June 05, 2017

DURHAM, N.C.–(BUSINESS WIRE)–Low-intensity pulsed ultrasound (LIPUS) treatment can be an effective alternative to surgery for nonunions, which are fractures that fail to heal. This according to a systematic review and meta-analysis of 13 published studies that describe nonunions treated with LIPUS. The findings were published in the May 15, 2017 issue of Injury available at http://www.injuryjournal.com/article/S0020-1383(17)30341-8/fulltext.

Nonunions occur in approximately 5% of patient fracture cases each year. Nonunions have little expectation of spontaneous healing and can be corrected with revision surgery, however such procedures typically pose technical challenges and an increased potential for complications. When surgery is optional and patients want to avoid its associated risks, choosing LIPUS has demonstrated a positive healing effect more than 80% of the time, which is comparable to the success rate for surgical treatment.

“This meta-analysis revealed that LIPUS is a viable alternative to surgery for established nonunions,” said Dr. R. Grant Steen, Manager of Medical Affairs, Bioventus. “The heal rate across all primary studies included was 82% and increased to 84% for nonunions that were eight months or older.”

The review and meta-analysis was funded by Bioventus and adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies were considered eligible for review if LIPUS was used as an alternative to surgery for non-healing fractures and if the treatment was applied at least three months after the last surgical procedure. In addition, at least one outcome of interest (heal/fail) was required and a clear definition of delayed or nonunion was included.

Authors of this study include Ross Leighton, MD, Dalhousie University; J. Tracy Watson, MD, Saint Louis University School of Medicine; Peter Giannoudis, MD, University of Leeds; Costas Papakostidis, MD, Chapel Allerton Hospital; Andrew Harrison, PhD, Bioventus and R. Grant Steen, PhD, Bioventus.

About Bioventus

Bioventus is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing. Its EXOGEN® Ultrasound Bone Healing System uses safe, effective low intensity pulsed ultrasound (LIPUS) to stimulate the body’s natural healing process. EXOGEN has been used to treat more than 1 million patients worldwide and numerous regulatory agencies including the FDA, Health Canada, BSi, TGA, Medsafe, UAE Ministry of Health and SFDA have granted their approval of the product. Today it is the leading bone healing system in the market with complaints for lack of efficacy averaging less than 1%.

Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.BioventusGlobal.com and follow the company on Twitter @Bioventusglobal.

Bioventus, the Bioventus logo and EXOGEN are registered trademarks of Bioventus LLC.

Contacts

Bioventus LLC
Thomas Hill, 919-474-6715
thomas.hill@bioventusglobal.com


AAEAAQAAAAAAAAfMAAAAJGE5NmNhN2ZjLWQyZjYtNGNkYy05OTUwLTM5MTliMGMxOWRjMQ.jpg

June 5, 2017 OrthoSpineNews

By kgrayson@bizjournals.com – May 30, 2017

Medtronic has joined in a $40 million round of equity financing for Saluda Medical, a med-tech company with operations in the Twin Cities.

Saluda is developing an implantable medical device to treat chronic back pain and other conditions using electrical pulses. The Australia-based company expanded into the United States two years ago, starting a seven-employee clinical research team in Bloomington, Minn.

The company plans to expand its Twin Cities operation following the round of funding, Saluda Medical Senior Vice President Dan Brounstein said in an email. “It is the place to start a medical device company and we are dedicated to continued growth.”

Action Potential Venture Capital, a venture arm of GlaxoSmithKline, led the round of funding. Medtronic was a return investor.

READ THE REST HERE


155748308.jpg

June 5, 2017 OrthoSpineNews

MELBOURNE, FL–(Marketwired – Jun 2, 2017) – First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) (“FCHS,” “First Choice” or the “Company”), one of the nation’s only non-physician-owned, publicly traded healthcare services companies focused on the delivery of total musculoskeletal solutions with an emphasis on Orthopaedics and spine care, today announced that its Board of Directors unanimously approved a program to repurchase up to one million shares of the company’s common stock.

The authorized repurchases will be made from time to time in either the open market, block transactions, or through privately negotiated transactions. The timing, volume and nature of share repurchases will be at the sole discretion of management, dependent on market conditions, applicable securities laws, and other factors, and may be suspended or discontinued at any time.

“The stock repurchase plan demonstrates our confidence in the strength of our business and commitment to delivering shareholder value,” said Chris Romandetti, President and CEO of First Choice. “We believe our valuation is attractive relative to industry peers and given the company has sufficient cash on hand to support our expansion plans, adding the flexibility to repurchase shares was prudent.”

No assurance can be given that any particular amount of common stock will be repurchased. This repurchase program has no expiration date and is subject to the company’s blackout periods. The program may be modified or terminated by the Board of Directors at any time. The Company will report the repurchases in its periodic reports filed with the U.S. Securities and Exchange Commission.

As of March 31, 2017, First Choice reported approximately $3.9 million in cash with an additional $1.4 million available on a credit facility. First Choice intends to use available cash and future cash flows from operations to fund the repurchase program.

About First Choice Healthcare Solutions, Inc.
Headquartered in Melbourne, Florida, First Choice Healthcare Solutions (FCHS) is implementing a defined growth strategy aimed at expanding its network of non-physician-owned medical centers of excellence, which concentrate on treating patients in the following specialties: Orthopaedics, Spine Surgery, Neurology, Interventional Pain Management and related diagnostic and ancillary services in key expansion markets throughout the Southeastern U.S. Serving Florida’s Space Coast, the Company’s flagship integrated platform currently administers over 100,000 patient visits each year and is comprised of First Choice Medical Group, The B.A.C.K. Center and Crane Creek Surgery Center. For more information, please visit www.myfchs.com, www.myfcmg.com, www.thebackcenter.net and www.cranecreeksurgerycenter.com.

Safe Harbor Statement
Certain information set forth in this news announcement may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of First Choice Healthcare Solutions, Inc. Such forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management beliefs and certain assumptions made by its management. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. Information concerning factors that could cause the Company’s actual results to differ materially from those contained in these forward-looking statements can be found in the Company’s periodic reports on Form 10-K and Form 10-Q, and in its Current Reports on Form 8-K, filed with the Securities and Exchange Commission. Unless required by law, the Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events, or otherwise to reflect future events or circumstances or reflect the occurrence of unanticipated events.

CONTACT INFORMATION


flx_0003_4.jpg

June 5, 2017 OrthoSpineNews

OR AKIVA, Israel, June 5, 2017 /PRNewswire/ —

Expanding Orthopedics Inc. (EOI), a privately-held medical device company focused on developing and commercializing innovative expandable devices for spine surgery, today announced CE mark of the FLXfit™15, enhancing the already successful FLXfit™ 3D expandable cage. The FLXfit™15 expands up to 4mm and enables controlled lordosis correction of up to 15⁰. There are two linear length options; a 40mm and a 32mm version.

The higher range expansion will enable surgeons to better treat their patients and restore lordosis angle up to 15⁰. The 32mm length option will offer great flexibility in treating patients with smaller anatomies. The ability to deliver the largest, in-class, TLIF, expandable cage with 4mm height expansion and 15 degrees of lordosis correction through a small unilateral tube is a paradigm change in the MIS fusion market.

Ofer Bokobza, CEO of Expanding Orthopedics, commented “Expandable cages are gaining market momentum and play a key role in successful MIS fusion procedures. The FLXfit™ 3D expandable cage introduced a new paradigm with expandable cages and is already making a significant traction in the market place. We are thrilled with the release of the FLXfit™15 as it represents our continued commitment for innovation and ability to deliver state-of-the-art spine fusion solutions.” He concluded, “We believe that the versatility of the new FLXfit™ family will help EOI gain a greater share in the fusion surgery market both in MIS and open approaches.”

The FLXfit™15 is the subject of a pending 510k and is not available for sale in the US.

About Expanding Orthopedics Inc.

Expanding Orthopedics Inc. is medical device company developing and marketing innovative products designed to address unmet clinical needs for spine care and improve long-term patients’ outcome. The Company is spearheaded by a seasoned management team, and is advised by a prominent team of spine surgeons. EOI owns a broad patent portfolio around anatomically fit, expandable devices for enhanced stability through a minimally invasive approach.
Contact info:
David Elkaim, VP Marketing and Sales
E-mail: david@xortho.com
Phone: (347)-3219683

SOURCE Expanding Orthopedics Inc.


Spreizer.jpg

June 5, 2017 OrthoSpineNews

Albany, NY — (SBWIRE) — 06/05/2017 — Interspinous spacers sometimes also called as Interspinous process decompression systems, are the devices implanted between vertebral spinous processes. These spacers are made up of a very strong but lightweight metal (titanium) which is biocompatible in the human body. These devices are imbedded in body to confine painful motion else enabling normal motion and to treat lumbar spinal stenosis, discogenic low-back pain, facet syndrome, disc herniations, and non-traumatic instability.

Lumbar spinal stenosis is a thinning of the spinal canal in the lower back which causes compression on nerves and it is developed gradually with age. Radiology tests are used to confirm a diagnosis of moderate degenerative lumbar spinal stenosis. People with lumbar spinal stenosis experience pain but may also have weakness in their leg, lower back and buttocks, numbness, tingling.

Obtain Report Details @ http://www.transparencymarketresearch.com/interspinous-spacer-market.html

The Interspinous spacer are implanted between those vertebrae in such a way that it prevents the patient from bending too far backward which causes pain by surgical procedure. The procedure is very small and sometimes patient can go home within a day.

The increasing prevalence of spinal stenosis due to aging, arthritis, heredity and increased demand of surgical procedures that improved lifestyle and comfort will drive the Interspinous spacer market. The adoption of spacers are increasing due to low complication rate as compared to decompression and spinal fusion. The Interspinous spacers are widely used in geriatric population as per Medicare data due to old age patient are not comfortable with surgery due to their health conditions.

The Interspinous spacer market is segmented as device type, end user and geography. The product type segment is further divided in two type’s statics or compressible and dynamic or non-compressible respectively. The examples of static devices include X STOP, ExtenSure and Wallis implants. These are made up of non-compressible material such as bone, metal or synthetics. The devices produce constant amount of distraction between the spinous processes due to their non-compressible nature. Dynamic Interspinous spacer devices have a degree of compressibility.

 

READ THE REST HERE


NuVasive_1_Full.jpg

June 5, 2017 OrthoSpineNews

SAN DIEGO, June 5, 2017 /PRNewswire/ — NuVasive, Inc. (NASDAQ: NUVA), a leading medical device company focused on transforming spine surgery with minimally disruptive, procedurally-integrated solutions, today announced the PRECICE® system and PRECICE UNYTE™ platform from NuVasive Specialized Orthopedics (NSO) are featured in the June 2017 supplement of the Journal of Orthopaedic Trauma (JOT), which demonstrates a lower complication rate, greater patient comfort and faster healing in comparison to traditional treatments1.

NSO, a NuVasive division focused on the design and innovation of disruptive orthopedic solutions, developed a proprietary platform of magnetically adjustable implant systems that include:

  • The PRECICE system is an intramedullary device that once implanted utilizes an External Remote Controller (ERC) to non-invasively lengthen the femur and tibia. Through propriety magnetic technology, the PRECICE ERC lengthens the PRECICE device with precision rate control. Each patient’s lengthening is customized based on a physician directed program.
  • PRECICE UNYTE is an intramedullary solution for stabilizing and treating difficult to heal fractures and non-unions. It leverages clinically validated technology based on the proven principles of compression and distraction osteogenesis and uses the ERC magnetic technology to apply non-invasive customized treatment for proper bone healing and restoring natural bone length.

“Our groundbreaking, non-invasive technology platforms from NSO have disrupted the spine and orthopedic markets,” said Gregory T. Lucier, NuVasive chairman and chief executive officer. “The positive outcomes from our early clinical experience with PRECICE UNYTE demonstrate that we are able to treat complex fractures with our magnetic technology, which will help transform the lives of patients that previously lacked a formidable solution.”

PRECICE system and PRECICE UNYTE are featured in the June JOT Supplement, “Intramedullary Limb Lengthening and Compression for Orthopedic Trauma Surgeons“, with five articles authored by leading surgeons Robert Rozbruch, M.D., Mitchell Bernstein, M.D., Stuart Green, M.D., Austin Fragomen, M.D., and Tracy Watson, M.D.

“I’m honored to report on the success of PRECICE UNYTE intramedullary compression implant and share the positive results of our early clinical experience,” said Dr. Green, University of California, Irvine, Department of Orthopaedic Surgery. “The future of this technology is clearly evident in the JOT supplement, which highlights the key role engineering research plays in developing medical device innovation. Patients around the globe will greatly benefit from the new technology created by the collaboration effort of NSO and the surgeon community.”

PRECICE UNYTE WEBINAR

The Company is hosting a webinar on June 6, 2017 titled, “Treating Challenging Fractures and Nonunions,” featuring Austin Fragomen, M.D. from the Hospital for Special Surgery, New York. The webinar will look at traditional treatment options and highlight new technologies in intramedullary compression and distraction devices. Click here for more information and to register.

About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is a world leader in minimally invasive, procedurally-integrated spine solutions. From complex spinal deformity to degenerative spinal conditions, NuVasive is transforming spine surgery and beyond with innovative technologies designed to deliver reproducible and clinically proven surgical outcomes. NuVasive’s highly differentiated, procedurally-integrated solutions include access instruments, implantable hardware and software systems for surgical planning and reconciliation technology that centers on achieving the global alignment of the spine. With $962 million in revenues (2016), NuVasive has an approximate 2,300 person workforce in more than 40 countries around the world. For more information, please visit www.nuvasive.com.

Forward-Looking Statements
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive’s results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company’s surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive’s products (including the iGA™ platform), the Company’s ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive’s news releases and periodic filings with the Securities and Exchange Commission. NuVasive’s public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.

1 Fragomen, Austin T. J Orthop Trauma; Volume 31, Number 6 Supplement, June 2017; S7-S13

 

SOURCE NuVasive, Inc.


arthrosight_home.png

June 2, 2017 OrthoSpineNews

LOWELL, Mass., June 1, 2017 /PRNewswire/ — Arthromeda, Inc., a developer of intelligent orthopedic navigation systems, closed its Series D financing to take the ArthroSight-PS Hip Alignment System (ArthroSight-PS) through commercial regulatory approvals and clinical validation.  This was achieved following a series of successful cadaver labs conducted by surgeon Daniel Ward, MD (New England Baptist Hospital, Boston, MA) at the Cincinnati Children’s Hospital and Medical Center translational research lab (Cincinnati, OH).  The cadaveric studies confirmed that the ArthroSight- PS is an intuitive All-in-One system for accurate and precise implant positioning, providing real-time position angles (inclination and anteversion), leg length and femoral offset difference measurements.  Videos from the labs can be found in Arthromeda’s newly released clinician and patient focused website www.arthromeda.com.

Accurate hip implant positioning is an extremely important factor for patients, physicians, regulators and device companies. In recent years, the number of hip surgeries has skyrocketed with increasing numbers of younger adults getting the procedure according to popular press reports.  Over the 10 years of the study, the number of procedures more than doubled, from 138,700 in 2000 to 310,800 in 2010. The number grew by 92 percent, to 80,000, among those aged 75 and older. It jumped by 205 percent in those aged 45 to 54, to 51,900. Due to the aging baby boomer population, the magnitude of the problem is projected to increase dramatically – doubling by 2030.

“Patient-specific solutions in surgery that are individualized to patients at an affordable cost are important. I am delighted to support Arthromeda in its game-changing mission to help patients undergoing hip arthroplasty experience superior outcomes,” commented Edgar D. Jannotta, Jr., Arthromeda Director and lead investor.

Elsa Chi Abruzzo, RAC, FRAPS, chief operating officer of Arthromeda, commented, “I am grateful to our founder and executive chairman, Mr. PJ Anand, for his clear strategic vision and leadership.  I also appreciate the technical insight of our cofounder and Chief Technical Officer, Mehran Aghazadeh, MD.  We are excited to execute on the next phase of development of this elegant solution for real-time, accurate, acetabular cup positioning and leg length and femoral offset adjustments, without the expensive capital investments or increased procedure time associated with robotic and imaged-based systems.”

Foley Hoag LLP, led by Life Sciences Practice chair Jeffrey Quillen and Patrick Connolly, represented Arthromeda in the financing.  Mr. Quillen & Connolly have represented Arthromeda since its founding in 2011.

About Arthromeda, Inc.

Founded in 2011, Arthromeda, Inc. is a private medical device company focused on developing intuitive, real-time, sensor based, intelligent technologies to improve surgical outcomes for patients undergoing joint replacement procedures.  As part of its extensive patent protected intellectual property portfolio, Arthromeda has created two distinct, yet complimentary, technology platforms to reduce operating room time, improve patient outcomes, and reduce the cost burden associated with early implant failure.   More information can be found at www.arthromeda.com

Contact:
Jennifer Williams
Cook Williams Communications, Inc.
360-668-3701
jennifer@cwcomm.org

 

SOURCE Arthromeda, Inc.

Related Links

http://www.arthromeda.com/


rti-surgical-corporate-photos-38-1200x801.jpg

June 2, 2017 OrthoSpineNews

June 02, 2017

ALACHUA, Fla.–(BUSINESS WIRE)–RTI Surgical (RTI) (Nasdaq: RTIX), a global surgical implant company, is part of a new public-private Manufacturing USA initiative, the Advanced Regenerative Manufacturing Institute (ARMI). Headquartered in Manchester, New Hampshire, ARMI is the twelfth Manufacturing USA institute. It brings together a consortium of nearly 100 partner organizations from industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs.

Approximately $80 million from the federal government will be combined with more than $200 million in cost share to support the development of tissue and organ manufacturing capabilities. As part of continuing efforts to help revitalize American manufacturing and incentivize companies to invest in new technology development in the United States, ARMI will lead the Advanced Tissue Biofabrication (ATB) Manufacturing USA Institute on behalf of the Department of Defense.

Under the umbrella of Manufacturing USA, a public-private network that invests in the development of world-leading advanced manufacturing technologies, ARMI will work to integrate and organize the fragmented collection of industry practices and domestic capabilities in tissue biofabrication technology in order to better position the US relative to global competition. ARMI will also focus on accelerating regenerative tissue research and creating state-of-the-art manufacturing innovations in biomaterial and cell processing for critical Department of Defense and civilian needs.

“We need to develop twenty-first century tools for engineered tissue manufacturing that will allow these innovations to be widely available – similar to how a fifteenth century tool (the printing press) allowed knowledge to spread widely during the Renaissance,” said inventor Dean Kamen, ARMI’s chairman.

ARMI’s efforts are supported by forty-seven industrial partners, twenty-six academic and academically affiliated partners, and fourteen government and nonprofit partners. The ARMI partnership continues to grow.

“RTI Surgical is pleased to participate in the ARMI consortium,” said Todd Goede, Global Vice President of Research and Development. “We look forward to providing the regenerative manufacturing resources and knowledge that we use every day to help patients – undoubtedly, the lives of many will benefit from the innovations this initiative will create.”

About RTI Surgical Inc.

RTI Surgical is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, general surgery, spine, orthopedic, trauma and cardiothoracic procedures and are distributed in nearly 50 countries. RTI is headquartered in Alachua, Fla., and has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com.

Forward Looking Statement

This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. In addition, except for historical information, any statements made in this communication about anticipated financial results, growth rates, new product introductions, future operational improvements and results or regulatory actions or approvals or changes to agreements with distributors also are forward-looking statements. These statements are not guarantees of future performance and are subject to risks and uncertainties, including the risks described in public filings with the U.S. Securities and Exchange Commission (SEC). Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Copies of the company’s SEC filings may be obtained by contacting the company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov.

About ARMI

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is the 12th Manufacturing USA Institute. It brings together a consortium of nearly 100 partners from across industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. ARMI will work to organize the current fragmented domestic capabilities in tissue biofabrication technology to better position the U.S. relative to global competition. For more information on ARMI, please visit www.ARMIUSA.org.

Contacts

RTI Surgical
Roxane Wergin, Phone: 386-418-8888
Director, Corporate Communications
rwergin@rtix.com